Selected research
Industry Research
Targeting p53 Cancer Therapies Industry Research Report 2026
Market perspective
The global Targeting p53 Cancer Therapies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Targeting p53 Cancer Therapies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Targeting p53 Cancer Therapies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Targeting p53 Cancer Therapies include Alieron Therapeutics, Aprea Therapeutics, Kartos Therapeutics, MultiVir, Rain Oncology, SynerGene Therapeutics, Jc (Wuxi) Company, Sibiono GeneTech and Ascentage Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Targeting p53 Cancer Therapies market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Targeting p53 Cancer Therapies Market by Company
Alieron Therapeutics
Aprea Therapeutics
Kartos Therapeutics
MultiVir
Rain Oncology
SynerGene Therapeutics
Jc (Wuxi) Company
Sibiono GeneTech
Ascentage Pharma
Targeting p53 Cancer Therapies Segment by Type
Gene Therapy
Immunotherapy
Small Molecule Drugs
Others
Targeting p53 Cancer Therapies Segment by Application
Hospital
Clinic
Others
Targeting p53 Cancer Therapies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting p53 Cancer Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeting p53 Cancer Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting p53 Cancer Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Targeting p53 Cancer Therapies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Targeting p53 Cancer Therapies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Targeting p53 Cancer Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gene Therapy
- Immunotherapy
- Small Molecule Drugs
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Alieron Therapeutics
- Aprea Therapeutics
- Kartos Therapeutics
- MultiVir
- Rain Oncology
- SynerGene Therapeutics
- Jc (Wuxi) Company
- Sibiono GeneTech
- Ascentage Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Targeting p53 Cancer Therapies Market Size (2021-2032)
- 2.2.2 Global Targeting p53 Cancer Therapies Sales (2021-2032)
- 2.2.3 Global Targeting p53 Cancer Therapies Market Average Price (2021-2032)
- 2.3 Targeting p53 Cancer Therapies by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Gene Therapy
- 2.3.3 Immunotherapy
- 2.3.4 Small Molecule Drugs
- 2.3.5 Others
- 2.4 Targeting p53 Cancer Therapies by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Targeting p53 Cancer Therapies Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Targeting p53 Cancer Therapies Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Targeting p53 Cancer Therapies Revenue of Manufacturers (2021-2026)
- 3.4 Global Targeting p53 Cancer Therapies Average Price by Manufacturers (2021-2026)
- 3.5 Global Targeting p53 Cancer Therapies Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Targeting p53 Cancer Therapies, Product Type & Application
- 3.8 Global Manufacturers of Targeting p53 Cancer Therapies, Established Date
- 3.9 Global Targeting p53 Cancer Therapies Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alieron Therapeutics
- 4.1.1 Alieron Therapeutics Company Information
- 4.1.2 Alieron Therapeutics Business Overview
- 4.1.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- 4.1.5 Alieron Therapeutics Recent Developments
- 4.2 Aprea Therapeutics
- 4.2.1 Aprea Therapeutics Company Information
- 4.2.2 Aprea Therapeutics Business Overview
- 4.2.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- 4.2.5 Aprea Therapeutics Recent Developments
- 4.3 Kartos Therapeutics
- 4.3.1 Kartos Therapeutics Company Information
- 4.3.2 Kartos Therapeutics Business Overview
- 4.3.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- 4.3.5 Kartos Therapeutics Recent Developments
- 4.4 MultiVir
- 4.4.1 MultiVir Company Information
- 4.4.2 MultiVir Business Overview
- 4.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio
- 4.4.5 MultiVir Recent Developments
- 4.5 Rain Oncology
- 4.5.1 Rain Oncology Company Information
- 4.5.2 Rain Oncology Business Overview
- 4.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
- 4.5.5 Rain Oncology Recent Developments
- 4.6 SynerGene Therapeutics
- 4.6.1 SynerGene Therapeutics Company Information
- 4.6.2 SynerGene Therapeutics Business Overview
- 4.6.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- 4.6.5 SynerGene Therapeutics Recent Developments
- 4.7 Jc (Wuxi) Company
- 4.7.1 Jc (Wuxi) Company Company Information
- 4.7.2 Jc (Wuxi) Company Business Overview
- 4.7.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
- 4.7.5 Jc (Wuxi) Company Recent Developments
- 4.8 Sibiono GeneTech
- 4.8.1 Sibiono GeneTech Company Information
- 4.8.2 Sibiono GeneTech Business Overview
- 4.8.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
- 4.8.5 Sibiono GeneTech Recent Developments
- 4.9 Ascentage Pharma
- 4.9.1 Ascentage Pharma Company Information
- 4.9.2 Ascentage Pharma Business Overview
- 4.9.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
- 4.9.5 Ascentage Pharma Recent Developments
5 Global Targeting p53 Cancer Therapies Market Scenario by Region
- 5.1 Global Targeting p53 Cancer Therapies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Targeting p53 Cancer Therapies Sales by Region: 2021-2032
- 5.2.1 Global Targeting p53 Cancer Therapies Sales by Region: 2021-2026
- 5.2.2 Global Targeting p53 Cancer Therapies Sales by Region: 2027-2032
- 5.3 Global Targeting p53 Cancer Therapies Revenue by Region: 2021-2032
- 5.3.1 Global Targeting p53 Cancer Therapies Revenue by Region: 2021-2026
- 5.3.2 Global Targeting p53 Cancer Therapies Revenue by Region: 2027-2032
- 5.4 North America Targeting p53 Cancer Therapies Market Facts & Figures by Country
- 5.4.1 North America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Targeting p53 Cancer Therapies Sales by Country (2021-2032)
- 5.4.3 North America Targeting p53 Cancer Therapies Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Targeting p53 Cancer Therapies Market Facts & Figures by Country
- 5.5.1 Europe Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2032)
- 5.5.3 Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Targeting p53 Cancer Therapies Market Facts & Figures by Country
- 5.6.1 Asia Pacific Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Targeting p53 Cancer Therapies Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Targeting p53 Cancer Therapies Market Facts & Figures by Country
- 5.7.1 South America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Targeting p53 Cancer Therapies Sales by Country (2021-2032)
- 5.7.3 South America Targeting p53 Cancer Therapies Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Targeting p53 Cancer Therapies Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032)
- 6.1.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2032)
- 6.2 Global Targeting p53 Cancer Therapies Revenue by Type (2021-2032)
- 6.2.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2032)
- 6.3 Global Targeting p53 Cancer Therapies Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032)
- 7.1.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2032)
- 7.2 Global Targeting p53 Cancer Therapies Revenue by Application (2021-2032)
- 7.2.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2032)
- 7.3 Global Targeting p53 Cancer Therapies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Targeting p53 Cancer Therapies Value Chain Analysis
- 8.1.1 Targeting p53 Cancer Therapies Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Targeting p53 Cancer Therapies Production Mode & Process
- 8.2 Targeting p53 Cancer Therapies Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Targeting p53 Cancer Therapies Distributors
- 8.2.3 Targeting p53 Cancer Therapies Customers
9 Global Targeting p53 Cancer Therapies Analyzing Market Dynamics
- 9.1 Targeting p53 Cancer Therapies Industry Trends
- 9.2 Targeting p53 Cancer Therapies Industry Drivers
- 9.3 Targeting p53 Cancer Therapies Industry Opportunities and Challenges
- 9.4 Targeting p53 Cancer Therapies Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst